Skip to main content

3 Result(s)

within Keenan T. Hartert Remove this filter

and

  1. No Access

    Article

    Integrative analyses reveal outcome-associated and targetable molecular partnerships between TP53, BRD4, TNFRSF10B, and CDKN1A in diffuse large B-cell lymphoma

    Diffuse large B-cell lymphoma (DLBCL) is a common, genomically heterogenous disease that presents a clinical challenge despite the success of frontline regimens and second-line chimeric antigen receptor T-cell...

    Aidan L. Forberg, Jordan Unrau, Kennedee S. Weber, Alison C. Rutz… in Annals of Hematology (2024)

  2. No Access

    Article

    Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL

    Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, and front line therapies have not improved overall outcomes since the advent of immunochemotherapy. By pairing DNA and gene expression data wi...

    Keenan T. Hartert, Kerstin Wenzl, Jordan E. Krull, Michelle Manske… in Leukemia (2021)

  3. Article

    Open Access

    Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients

    Double/triple hit lymphoma (DH/TH), known as high-grade B-cell lymphoma (HGBL), is an aggressive diffuse large B cell lymphoma (DLBCL), defined as having concurrent MYC, BCL2, and/or BCL6 gene rearrangements. Whi...

    Jordan E. Krull, Kerstin Wenzl, Keenan T. Hartert… in Blood Cancer Journal (2020)

    Download PDF (1384 KB) View Article